Skip to main content

Table 2 Patterns of failure and survival in cervical cancers with pelvic, para-aortic and/or supraclavicular lymph node metastasis treated with PET-guided extended-field dose-escalating chemo-IMRT/3D-brachytherapy

From: Patterns of failure after use of 18F-FDG PET/CT in integration of extended-field chemo-IMRT and 3D-brachytherapy plannings for advanced cervical cancers with extensive lymph node metastases

Outcomes Pelvic LAP Paraaortic LAP SC LAP Total (%)
Dead/Total 5/26 12/31 6/15 23/72 (31.9)
In-field failure-only (cervix, lymph nodes) 2 5 1 8 (11.1)
Out-of-field failure-only (lymph node, bone and/or visceral metastases) 5 8 5 18 (25.0)
Both failures 1 2 0 3 (4.2)
Survival
 1-year DFS (%) 91.7 89.9 75.0
 3-year DFS (%) 78.5 55.8 75.0
 5-year DFS (%) 78.5 41.8 50.0
  1. Abbreviations: CCRT concurrent chemoradiotherapy, IMRT/IGRT intensity-modulated and image-guided radiotherapy, LAP lymphadenopathy, DFS disease-free survival, PET fluorodeoxyglucose position emission computed tomography